DBV Technologies: towards a change in ADS ratio
The biopharmaceutical company thus plans to change the current ratio of one ADS for half an ordinary share to a new ratio of one ADS for one ordinary share, a change which should be effective on June 3.
The operation is designed to enable DBV to comply with the Nasdaq requirement of a floor price for its ADSs of over one dollar. It will therefore halve the number of ADSs and have no impact on ordinary shares.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction